NexImmune (NEXI) SEC Filings & 10K Form $0.23 -0.04 (-14.77%) (As of 12/20/2024 04:04 PM ET) Add Compare Share Share SEC Filings Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Recent NexImmune SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView09/06/20246:41 AMNasdaq Stock Market LLC (Filed by)NexImmune (Subject)Form 25-NSE08/28/202411:15 PMNexImmune (Filer)Form EFFECT08/27/20243:10 PMNexImmune (Filer)Form S-8 POS08/27/20243:01 PMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 08/27/20243:03 PMNexImmune (Filer)Form POS AM08/27/20243:06 PMNexImmune (Filer)Form S-8 POS08/27/20243:08 PMNexImmune (Filer)Form S-8 POS07/19/20243:01 PMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 07/19/20243:03 PMNexImmune (Filer)Form DEFA14A07/11/20242:10 PMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 07/11/20242:12 PMNexImmune (Filer)Form DEFA14A06/21/20246:30 AMNexImmune (Filer)Form DEF 14A06/13/20246:58 PMJones Kristi (Reporting)NexImmune (Issuer)Form 4Statement of changes in beneficial ownership of securities 06/11/20244:17 PMNexImmune (Filer)Form PRE 14A05/20/20244:10 PMNexImmune (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 04/10/20244:13 PMMarchio Albert N II (Reporting)NexImmune (Issuer)Form 3Initial statement of beneficial ownership of securities 02/06/20243:30 PMNexImmune (Filer)Form DEFA14A02/05/20244:10 PMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/05/20243:34 PMNexImmune (Filer)Form 424B502/02/202412:25 PMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/01/20248:17 AMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 01/19/20243:43 PMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 01/18/20243:43 PMNexImmune (Filer)Form DEFA14A12/22/20233:01 PMNexImmune (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies Psyence Biomedical 10K Form CohBar 10K Form Oncternal Therapeutics 10K Form Galera Therapeutics 10K Form Eterna Therapeutics 10K Form China SXT Pharmaceuticals 10K Form Panbela Therapeutics 10K Form Revelation Biosciences 10K Form Kiromic BioPharma 10K Form Altamira Therapeutics 10K Form SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:NEXI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
